Nycomed's Protonix patent upheld

ZURICH, Switzerland A U.S. District Court has ruled in favor of two companies who alleged patent infringement in another company’s attempt to market a generic version of their stomach acid drug.

Judge Jose Linares of the U.S. District Court for the District of New Jersey upheld a jury verdict in April in ruling against KUDCo, the generics business of the Schwarz Pharma Group, which had attempted to market a generic version of Protonix (pantoprazole). Nycomed owns the patent for Protonix and licensed it to Wyeth, which Pfizer acquired last year; the patent expires in January 2011.

“We are very pleased that the court recognized and acknowledged that our patent is valid,” Nycomed CEO Hakan Bjorklund said. “Patents represent the foundation of pharmaceutical innovation and are crucial to bring new medicines and treatments to patients who need them.”

Login or Register to post a comment.